Logo
x

Search

Subscribe Now

fibrosis

BMS to Acquire Forbius for its AVID200 to Expand its Footprints in Oncology and Fibrosis

BMS to Acquire Forbius for its AVID200 to Expand its Footprints in Oncology and Fibrosis

  • August 24, 2020
WuXi Biologics and Aravive Collaborate to Develop Novel High-Affinity Bispecific Antibodies for Cancer and Fibrosis

WuXi Biologics and Aravive Collaborate to Develop Novel High-Affinity Bispecific Antibodies for Cancer and Fibrosis

  • May 1, 2020
Galapagos Signs an Exclusive Option to License Agreement with Fibrocor to Expand their Existing 2019 Partnership for Fibrosis

Galapagos Signs an Exclusive Option to License Agreement with Fibrocor to Expand their Existing 2019 Partnership for Fibrosis

  • January 16, 2020
Gilead Reports Results of Selonsertib in P-III STELLAR 3 Study for Bridging Fibrosis (F3) due to NASH

Gilead Reports Results of Selonsertib in P-III STELLAR 3 Study for Bridging Fibrosis (F3) due to NASH

  • April 26, 2019
ReCode Therapeutics Reports the Preclinical Data of RCT2100 for Cystic Fibrosis

    ReCode Therapeutics Reports the Preclinical Data of RCT2100 for Cystic Fibrosis

    • September 27, 2024
    Boehringer Ingelheim Reports the P-III (FIBRONEER-IPF) Trial Data of Nerandomilast to Treat Idiopathic Pulmonary Fibrosis (IPF)

      Boehringer Ingelheim Reports the P-III (FIBRONEER-IPF) Trial Data of Nerandomilast to Treat Idiopathic Pulmonary Fibrosis (IPF)

      • September 16, 2024
      BioCity Biopharma Reports the P-II (2-SUCCEED) Study Data of SC0062 to Treat IgA Nephropathy

        BioCity Biopharma Reports the P-II (2-SUCCEED) Study Data of SC0062 to Treat IgA Nephropathy

        • July 8, 2024
        GSK Reports the Japanese MHLW’s Approval of Omjjara (momelotinib) for Treating Myelofibrosis

          GSK Reports the Japanese MHLW’s Approval of Omjjara (momelotinib) for Treating Myelofibrosis

          • June 25, 2024
          Alternative Treatment: Kurt Harrington from Ventoux Biosciences in a Gripping Conversation with PharmaShots

            Alternative Treatment: Kurt Harrington from Ventoux Biosciences in a Gripping Conversation with PharmaShots

            • May 29, 2024
            Vicore Highlights the P-IIa (AIR) Study Data of Buloxibutid for the Treatment of Idiopathic Pulmonary Fibrosis at ATS 2024

              Vicore Highlights the P-IIa (AIR) Study Data of Buloxibutid for the Treatment of Idiopathic Pulmonary Fibrosis at ATS 2024

              • May 20, 2024
              Image

              Incisive News in 3 Shots.

              Contact Us

              Our Information

              Follow Us

              Copyright © 2025 PharmaShots - All Rights Reserved.